Meeting
2024 ASCO Annual Meeting
Correlation of the combination of CT-derived tumor texture and vessel tortuosity on survival outcomes for immunotherapy but not for chemotherapy in metastatic non-small cell lung cancer (mNSCLC): Results from a CheckMate227 (CM227) subset.
Authors
Pushkar Mutha
Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, Atlanta, GA
Pushkar Mutha , Mohammadhadi Khorrami , Babajide Sonuga , Kshitij Aggarwal , Wiem Safta , Diederik J. Grootendorst , David Paulucci , Oana Mustatea , Brook Nepon Sixt , David Witt , Hilmi Al-Shakhshir , Vidya Sankar Viswanathan , Jeremy Callahan , Vamsidhar Velcheti , Anant Madabhushi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8610)
DOI
10.1200/JCO.2024.42.16_suppl.8610
Abstract #
8610
Poster Bd #
474
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non–small cell lung cancer (NSCLC): Results from CheckMate 227.
First Author: Julie R. Brahmer
Poster
2021 ASCO Annual Meeting
Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
First Author: Luis G. Paz-Ares
Poster
2019 ASCO Annual Meeting
Anti-PD-1/PD-L1 plus chemotherapy versus chemotherapy alone in first-line treatment for patients with metastatic NSCLC that were PD-L1 negative or less than 1 %.
First Author: Thierry Landre
Poster
2024 ASCO Annual Meeting
A phase 2/3 study of fianlimab, cemiplimab, plus chemotherapy versus cemiplimab plus chemotherapy in first-line treatment of advanced non-small cell lung cancer.
First Author: Nashat Gabrail